Home›Trial›NCT06398743
NCT06398743ACTIVE NOT RECRUITING

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

Study Summary

The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.

Conditions
Colorectal Cancer
Interventions / Drugs
MRD
View on ClinicalTrials.gov ↗
Sponsor
EXAS
Exact Sciences
Diagnostics
D43/100
Study Details
Enrollment416 participants
Primary Completion—
Lead SponsorExact Sciences Corporation
Data Retrieved2026-04-11 04:13:38.204274+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 416 participants
Sponsor Catalyst Profile

Exact Sciences (EXAS) is the sponsoring company for this trial. BiotechSign currently grades this company D (43/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

EXAS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.